An updated patent review of anaplastic lymphoma kinase inhibitors (2018–2022)

References

• Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141(7):1117–1134.
   PubMed Web of Science ®Google Scholar
• Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-hodgkin’s lymphoma. Science. 1994;263(5151):1281–1284. DOI:10.1126/science.8122112
   PubMed Web of Science ®Google Scholar
• Lee CC, Jia Y, Li N, et al. Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. Biochem J. 2010;430(3):425–437. DOI:10.1042/BJ20100609
   PubMedGoogle Scholar
• Kornev AP, Haste NM, Taylor SS, et al. Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism. Proc Natl Acad Sci. 2006;103(47):17783–17788.
   PubMed Web of Science ®Google Scholar
• Tartari CJ, Gunby RH, Coluccia AML, et al. Characterization of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase. J Biol Chem. 2008;283(7):3743. DOI:10.1074/jbc.M706067200
   PubMed Web of Science ®Google Scholar
• Roberto C, Claudia V, Chiara A, et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer. 2008;8(1):11–23. DOI:10.1038/nrc2291
   PubMed Web of Science ®Google Scholar
• Chioureas D, Beck J, Baltatzis G, et al. ALK+ anaplastic large cell lymphoma (ALCL)-derived exosomes carry ALK signalling proteins and interact with tumor microenvironment. Cancers. 2022;14(12):2939. DOI:10.3390/cancers14122939
   PubMed Web of Science ®Google Scholar
• Chen S, Wang B, Fu X, et al. Alkal1gene silencing prevents colorectal cancer progression via suppressing Sonic Hedgehog (SHH) signaling pathway. J Cancer. 2021;12(1):150–162. DOI:10.7150/jca.46447
   PubMed Web of Science ®Google Scholar
• Bitter MA, Franklin WA, Larson RA, et al. Morphology in Ki-1 (CD30)-positive non Hodgkin's lymphoma is correlated with clinical features and the presence of a unique chromosomal abnormality, t(2;5)(p23;q35). Am J Surg Pathol. 1990;14(4):305–316. DOI:10.1097/00000478-199004000-00001
   PubMed Web of Science ®Google Scholar
• Zhao ZH, Verma V, Zhang MT. Anaplastic lymphoma kinase: role in cancer and therapy perspective. Cancer Biol Ther. 2015;16(12):1691–1701.
   PubMed Web of Science ®Google Scholar
• Coffin CM, Patel A, Perkins S, et al. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol. 2001;14(6):569–576. DOI:10.1038/modpathol.3880352
   PubMed Web of Science ®Google Scholar
• Griffin CA, Hawkins AL, Dvorak C, et al. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res. 1999;59(12):2776–2780.
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–566. DOI:10.1038/nature05945
   PubMed Web of Science ®Google Scholar
• Webb TR, Slavish J, George RE, et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther. 2009;9(3):331–356. DOI:10.1586/14737140.9.3.331
   PubMed Web of Science ®Google Scholar
• Cerchietti L, Damm-Welk C, Vater I, et al. Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas. PLoS ONE. 2011;6(4):e18436. DOI:10.1371/journal.pone.0018436
   PubMed Web of Science ®Google Scholar
• Pulford K, Falini B, Banham AH, et al. Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. Blood. 2000;96(4):1605–1607. DOI:10.1182/blood.V96.4.1605
   PubMed Web of Science ®Google Scholar
• Passoni L, Longo L, Collini P, et al. Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients. Cancer Res. 2009;69(18):7338–7346. DOI:10.1158/0008-5472.CAN-08-4419
   PubMed Web of Science ®Google Scholar
• Lamant L, Pulford K, Bischof D, et al. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol. 2000;156(5):1711–1721. DOI:10.1016/S0002-9440(10)65042-0
   PubMed Web of Science ®Google Scholar
• Shackelford RE, Vora M, Mayhall K, et al. ALK-rearrangements and testing methods in non-small cell lung cancer: a review. Genes Cancer. 2014;5(1–2):1–14.
   PubMedGoogle Scholar
• van Gaal JC, Flucke UE, Roeffen MHS, et al. Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications. J Clin Oncol. 2012;30(3):308–315. DOI:10.1200/JCO.2011.37.8588
   PubMed Web of Science ®Google Scholar
• Mossé YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008;455(7215):930–935. DOI:10.1038/nature07261
   PubMed Web of Science ®Google Scholar
• Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase I study. Lancet Oncol. 2012;13(10):1011–1019. DOI:10.1016/S1470-2045(12)70344-3
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–2394. DOI:10.1056/NEJMoa1214886
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–2177. DOI:10.1056/NEJMoa1408440
   PubMed Web of Science ®Google Scholar
• Shaw AT, Spigel DR, Tan DS, et al. MINI01.01: whole body and intracranial efficacy of ceritinib in ALK-inhibitor naïve patients with ALK+ NSCLC and brain metastases: results of ASCEND 1 and 3. J Thorac Oncol. 2016;11(11):S256. DOI:10.1016/j.jtho.2016.09.016
   PubMed Web of Science ®Google Scholar
• Crinò L, Ahn MJ, De Marinis F, et al. Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK -rearranged non–small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2. J Clin Oncol. 2016;34(24):2866–2873. DOI:10.1200/JCO.2015.65.5936
   PubMed Web of Science ®Google Scholar
• Soria JC, Tan DS, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK rearranged non-small cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017;389(10072):917–929. DOI:10.1016/S0140-6736(17)30123-X
   PubMed Web of Science ®Google Scholar
• Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non–small cell lung cancer. Cancer Discov. 2014;4(6):662–673. DOI:10.1158/2159-8290.CD-13-0846
   PubMed Web of Science ®Google Scholar
• Ou SH, Ahn JS, De Petris L, et al. Alectinib in crizotinib-refractory ALK-Rearranged Non–Small-cell lung cancer: a phase II global study. J Clin Oncol. 2016;34(7):661–668. DOI:10.1200/JCO.2015.63.9443
   PubMed Web of Science ®Google Scholar
• Kodama T, Hasegawa M, Takanashi K, et al. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol. 2014;74(5):1023–1028. DOI:10.1007/s00280-014-2578-6
   PubMed Web of Science ®Google Scholar
• Larkins E, Blumenthal GM, Chen H, et al. FDA approval: alectinib for the treatment of metastatic, ALK-Positive Non–Small cell lung cancer following crizotinib. Clin Cancer Res. 2016;22(21):5171–5176. DOI:10.1158/1078-0432.CCR-16-1293
   PubMed Web of Science ®Google Scholar
• Huang WS, Liu S, Zou D, et al. Discovery of brigatinib (AP26113), a phosphine oxide-containing, potent, orally active inhibitor of anaplastic lymphoma kinase. J Med Chem. 2016;59(10):4948–4964. DOI:10.1021/acs.jmedchem.6b00306
   PubMed Web of Science ®Google Scholar
• Zhang S, Anjum R, Squillace R, et al. The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first-and second generation ALK inhibitors in preclinical models. Clin Cancer Res. 2016;22(22):5527–5538. DOI:10.1158/1078-0432.CCR-16-0569
   PubMed Web of Science ®Google Scholar
• Ardini E, Menichincheri M, Banfi P, et al. Entrectinib, a pan–TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications. Mol Cancer Ther. 2016;15(4):628–639. DOI:10.1158/1535-7163.MCT-15-0758
   PubMed Web of Science ®Google Scholar
• Liu D, Offin M, Harnicar S, et al. Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors. Ther Clin Risk Manag. 2018;14:1247–1252.
   PubMed Web of Science ®Google Scholar
• Rolfo C, Dziadziuszko R, Doebele RC, et al. Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumors: integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001. Ann Oncol. 2019;30(Supplement_5):v180. DOI:10.1093/annonc/mdz244.038
   Google Scholar
• De Braud F, Niger M, Damian S, et al. Alka-372-001: first-in-human, phase I study of entrectinib – an oral pan-trk, ROS1, and ALK inhibitor – in patients with advanced solid tumors with relevant molecular alterations. J Clin Oncol. 2015;33(15_suppl):abstr 2517. DOI:10.1200/jco.2015.33.15_suppl.2517
   Web of Science ®Google Scholar
• Patel MR, Bauer TM, Liu SV, et al. STARTRK-1: phase 1/2a study of entrectinib, an oral Pan-Trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. J Clin Oncol. 2015;33(15_suppl):abstr 2596. DOI:10.1200/jco.2015.33.15_suppl.2596
   Web of Science ®Google Scholar
• Drilon A, Siena S, Ou S, et al. Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017;7(4):400–409. DOI:10.1158/2159-8290.CD-16-1237
   PubMed Web of Science ®Google Scholar
• Li T, Ma W, Tian EC. Ensartinib (X-396): what does it add for patients with ALK-rearranged NSCLC. Chin Clin Oncol. 2019;8(S1):S4.
   PubMedGoogle Scholar
• Singhi EK, Horn L. Background and rationale of the eXalt3 trial investigating X-396 in the treatment of ALK+ non-small-cell lung cancer. Future Oncol. 2018;14(18):1781–1787.
   PubMed Web of Science ®Google Scholar
• Horn L, Infante JR, Reckamp KL, et al. Ensartinib (X-396) in ALK-positive non–small cell lung cancer: results from a first-in-human phase I/II, multicenter study. Clin Cancer Res. 2018;24(12):2771–2779. DOI:10.1158/1078-0432.CCR-17-2398
   PubMed Web of Science ®Google Scholar
• Basit S, Ashraf Z, Lee K, et al. First macrocyclic 3rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: clinical and designing strategy update of lorlatinnib. Eur J Med Chem. 2017;134:348–356.
   PubMed Web of Science ®Google Scholar
• Johnson TW, Richardson PF, Bailey S, et al. Discovery of (10 R)-7-Amino-12-fluoro-2, 10, 16-trimethyl-15-oxo-10, 15, 16, 17-tetrahydro-2H-8, 4-(metheno)pyrazolo [4, 3-h][2, 5, 11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ROS oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem. 2014;57:4720–4744.
   PubMed Web of Science ®Google Scholar
• Kong X, Pan P, Sun H, et al. Drug discovery targeting anaplastic lymphoma kinase (ALK). J Med Chem. 2019;62(24):10927–10954. DOI:10.1021/acs.jmedchem.9b00446
   PubMed Web of Science ®Google Scholar
• Collier TL, Normandin MD, Stephenson NA, et al. Synthesis and preliminary PET imaging of 11C and 18F isotopologues of the ROS1/ALK inhibitor lorlatinib. Nat Commun. 2017;8(1):15761. DOI:10.1038/ncomms15761
   PubMedGoogle Scholar
• Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017;18(12):1590–1599. DOI:10.1016/S1470-2045(17)30680-0
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654–1667. DOI:10.1016/S1470-2045(18)30649-1
   PubMed Web of Science ®Google Scholar
• CortellisTM Drug Discovery Intelligence [DB/OL]. https://www.cortellis.com/drugdiscovery
   Google Scholar
• Wang L, Gao M, Tong M, et al. Pharmacologic characterization of CT-711, a novel dual inhibitor of ALK and c-Met. Am J Cancer Res. 2018;8(8):1541–1550.
   PubMed Web of Science ®Google Scholar
• Ma YX, Zhao HY, Xue JH, et al. First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements. Eur J Cancer. 2022;173:238–249.
   PubMed Web of Science ®Google Scholar
• Lu S, Pan H, Wu L, et al. 8MO the efficacy and safety of TQ-B3101 monotherapy in the first-line treatment in patients with ROS1-positive non-small cell lung cancer. J Clin Oncol. 2022;33:S31.
   Google Scholar
• Fang Y, Pan HM, Lu S, et al. A phase I study to evaluate safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TQ-B3101. J Clin Oncol. 2020;38(15_suppl):e21705. DOI:10.1200/JCO.2020.38.15_suppl.e21705
   Web of Science ®Google Scholar
• Ou S, Nagasaka M, Brazel D, et al. Will the clinical development of 4th-generation “double mutant active” ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC? Transl Oncol. 2021;14(11):101191. DOI:10.1016/j.tranon.2021.101191
   PubMed Web of Science ®Google Scholar
• Cui JJ, Rogers E, Zhai DY, et al. Abstract 5226: tPX-0131: a next generation macrocyclic ALK inhibitor that overcomes ALK resistant mutations refractory to current approved ALK inhibitors. Cancer Res. 2020;80(Supplement_16):5226. DOI:10.1158/1538-7445.AM2020-5226
   Web of Science ®Google Scholar
• Murray BW, Zhai D, Deng W, et al. TPX-0131, a potent CNS-penetrant, next-generation inhibitor of wild-type ALK and ALK-resistant mutations. Mol Cancer Ther. 2021;20(9):1407–1499. DOI:10.1158/1535-7163.MCT-21-0221
   Web of Science ®Google Scholar
• Zhai D, Wei D, Rogers E, et al. Abstract B186: tPX-0005, a polypharmacology inhibitor, overcomes ALK treatment resistance from acquired mutations, bypass signaling, and EMT[C]/Abstracts. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics October 26-30, 2017; Philadelphia, PA. 2018.
   Google Scholar
• Drilon A, SHI O, Cho BC, et al. Repotrectinib (TPX-0005) is a next generation ROS1/TRK/ALK inhibitor that potently inhibits ROS1/TRK/ALK solvent front mutations. Cancer Discov. 2018;8(10):1227–1236. DOI:10.1158/2159-8290.CD-18-0484
   PubMed Web of Science ®Google Scholar
• Fan YQ, Zhang YJ, Liu Y, et al. Pyrizolo [1,5-a] pyrimidine derivatives of the second-generation TRK inhibitor: design, synthesis and biological evaluation. Bioorg Med Chem Lett. 2022;63:128646.
   PubMed Web of Science ®Google Scholar
• Liu XL, Zhang L, Wan HW, et al. Discovery and preclinical evaluations of WX-0593, a novel ALK inhibitor targeting crizotinib-resistant mutations. Bioorg Med Chem Lett. 2022;66:128730.
   PubMed Web of Science ®Google Scholar
• Fang Douglas D, Tao R, Wang GF, et al. Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models. BMC Cancer. 2022;22(1):752. DOI:10.1186/s12885-022-09799-4
   PubMed Web of Science ®Google Scholar
• Luo QY, Zhou SN, Pan WT, et al. A multi-kinase inhibitor APG-2449 enhances the antitumor effect of Ibrutinib in esophageal squamous cell carcinoma via EGFR/FAK pathway inhibition. Biochem Pharmacol. 2021;183:114318.
   PubMed Web of Science ®Google Scholar
• Xing PY, Zhao Q, Zhang L, et al. Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study. BMC Med. 2022;20(1):453. DOI:10.1186/s12916-022-02646-0
   PubMed Web of Science ®Google Scholar
• Liang CX, Zhang NN, Tan QY, et al. CT-707 overcomes resistance of crizotinib through activating PDPK1- AKT1 pathway by targeting FAK. Curr Cancer Drug Targets. 2019;19(8):655–665. DOI:10.2174/1568009618666181031152140
   PubMed Web of Science ®Google Scholar
• Mesaros EF, Ott GR, Dorsey BD. Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review. Expert Opin Ther Pat. 2014;24(4):417–442.
   PubMed Web of Science ®Google Scholar
• Liu YM, Kuo CN, Liou JP. Anaplastic lymphoma kinase inhibitors: an updated patent review (2014–2018). Expert Opin Ther Pat. 2020;30(5):351–373.
   PubMed Web of Science ®Google Scholar
• Arromax Pharmatech. Diphenylamino pyrimidine and triaizine compounds, its pharmaceutical composition and purposes. WO2018018986A1 (2018)
   Google Scholar
• Innovative Drug Research Center of Qingyuan Zhongda. Novel pyrimidine derivative of sulfinyl anilino and application of novel pyrimidine derivative in preparation of antitumor drugs. CN113501808A (2021)
   Google Scholar
• Sichuan Provincial People’s Hospital. Antitumor compound and application thereof. CN111704603A (2020)
   Google Scholar
• Raghavendra NM, Pingili D, Kadasi S, et al. Dual or multi-targeting inhibitors: the next generation anticancer agents. Eur J Med Che. 2018;143:1277–1300.
   PubMed Web of Science ®Google Scholar
• Chongqing Medical University. A class of HDAC/ALK dual-target inhibitors and methods for their preparation and applications. CN109593065A (2019).
   Google Scholar
• Shenyang Pharmaceutical University. 2,4-Diarylaminopyrimidine derivatives containing aromatic heterocycles and their preparation and application. CN111484484A (2020)
   Google Scholar
• Scorei RI, Popa R. Boron-containing compounds as preventive and chemotherapeutic agents for cancer. Anti-Cancer Agent Me. 2010;10(4):346–351.
   PubMed Web of Science ®Google Scholar
• Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. Boron-containing compound as tyrosine kinase inhibitor. CN108341835A (2018).
   Google Scholar
• Kechao LU, Xu Z, Wang X. Cadmium-sensitive measurement using a nano-copper-enhanced carbon fiber electrode. Sensors. 2019;19(22):WO2019149128A1.
   Web of Science ®Google Scholar
• Timmins GS. Deuterated drugs: where are we now? Expert Opin Ther Pat. 2014;24(10):1067–1075.
   PubMed Web of Science ®Google Scholar
• Deuracor therapeutic, Inc. Compound used as ALK kinase inhibitor and use thereof. WO2019007293A1 (2019).
   Google Scholar
• The University of Michigan. Aminopyrimidines as alk inhibitors. US11110090B2 (2021)
   Google Scholar
• Shenzhen University. 2-aniline-based pyrimidine derivatives and preparation method and application thereof. CN115448906A (2022)
   Google Scholar
• Centaurus Biopharma Co., Ltd. A kind of anaplastic lymphoma kinase inhibitor and its preparation method and application. WO2018127184A1 (2018)
   Google Scholar
• Centaurus Biopharma Co., Ltd. A kind of anaplastic lymphoma kinase inhibitor and its preparation method and application. CN107936024A (2018)
   Google Scholar
• Hang Zhou REX Pharmaceutical Co., Ltd. Benzofuran pyrazole amine protein kinase inhibitor. WO2018001251A1 (2018)
   Google Scholar
• Shenzhen TargetRx Inc. Indazole compound for use in inhibiting kinase activity, composition and application thereof. US11267806B2 (2022).
   Google Scholar
• Shanghai synergy pharmaceutical sciences Co., Ltd. Multi-target anti-tumor compound, preparation method therefor and use thereof. WO2021197467A1 (2021).
   Google Scholar
• The University of Michigan. 5,6-dihydro-11H-indoles simultaneously [2,3-b]quinoline-11-ketone as ALK inhibitor. WO2018094134A1 (2018)
   Google Scholar
• Cgenetech Co., Ltd. Compound having ALK inhibitory activity, preparation method therefor and use thereof. WO2022237813A1 (2022)
   Google Scholar
• Nanjing Leizheng Pharmaceutical Technology Co., Ltd & Jiangnan University. Benzoxadiazatetetradecene derivatives and use thereof. CN111362967A (2020)
   Google Scholar
• Wuhan Yuxiang Medical Technology Co., Ltd. Big ring analog derivative and its preparation method and application as kinases inhibitor. CN110357905A (2019)
   Google Scholar
• Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. Macrocyclic compounds as ALK and ROS modulators. CN112812128A (2021)
   Google Scholar
• NUVALENT, Inc. Heteroaromatic macrocyclic ether chemotherapeutic agents. WO2021226208A2 (2021)
   Google Scholar
• China Pharmaceutical University. Polysubstituted triaryl macrocyclic compounds and application thereof. CN114394974A
   Google Scholar
• Southeast Pharmaceuticals Co., Ltd. A class of fourteen - membered gelled ring derivatives application thereof. CN115246843A
   Google Scholar
• Tetranov Inc. Compound and its application as protein kinase regulator. CN109516999A (2019)
   Google Scholar
• Chengdu Haibowei Pharmaceutical Co., Ltd. Compound as protein kinase inhibitor and preparation method and application thereof. CN112110938A (2020).
   Google Scholar
• Guangzhou Baiting Medicine Technology Co. Ltd. Chiral macrocyclic compounds as protein kinase inhibitors and uses thereof. CN114763360A (2022)
   Google Scholar
• Turning point therapeutics, Inc. Macrocycles for use in treating disease. WO2020257165A1 (2020)
   Google Scholar
• TYK Medicines, Inc. Compound used as kinase inhibitor and application thereof. WO2020224626A1 (2020)
   Google Scholar
• TYK Medicines, Inc. Compound used as kinase inhibitor and application thereof. WO2022095910A1 (2022)
   Google Scholar
• Zhejiang University. Pyrazolo[3,4-b]pyridine compounds and their and its preparation method and application. CN108774224A (2018)
   Google Scholar
• Jiangsu Skyrun Pharmaceuticals Co., Ltd. 2-Amino-pyrrolopyrimidine and pyrazolopyrimidine compounds, and preparation method and application thereof. CN111484496A (2020)
   Google Scholar
• Haipeng C. A kind of tricyclic compounds containing cyano and its purposes in the preparation of antitumor drugs. CN108558886A (2018)
   Google Scholar
• Jiangsu Vocational College of Medicine. [1,2,4] the triazine simultaneously hydrochloride of [6,1-a]iso-indoles compound and its application. CN108047231A (2018)
   Google Scholar
• China Pharmaceutical University. Intracellular self-assembly ALK depressant based on biological orthogonal strategy and its preparation and application preparation method therefor and use thereof. CN115417858A
   Google Scholar
• Mok T, Camidge DR, Gadgeel SM, et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol. 2020;31(8):1056–1064. DOI:10.1016/j.annonc.2020.04.478
   PubMed Web of Science ®Google Scholar
• Li Z, Liu F, Wu S, et al. Research progress on the drug resistance of ALK kinase inhibitors. Curr Med Chem. 2022;29(14):2456–2475. DOI:10.2174/0929867328666210806120347
   PubMed Web of Science ®Google Scholar
• Pan P, Yu H, Liu Q, et al. Combating drug-resistant mutants of anaplastic lymphoma kinase with potent and selective type-i1/2 inhibitors by stabilizing unique DFG-shifted loop conformation. ACS Central Sci. 2017;3(11):1208–1220. DOI:10.1021/acscentsci.7b00419
   PubMed Web of Science ®Google Scholar
• Cui YB, Tan ZH, Liu SY, et al. Fragment-based discovery of novel phenyltriazolyl derivatives as allosteric type-I1/2 ALK inhibitors with promising antitumor effects. Bioorg Med Chem Lett. 2022;75:128990.
   PubMed Web of Science ®Google Scholar
• Miao XQ, Xing LY, Guo M, et al. Design, synthesis and biological evaluation of 2-arylaminopyrimidine derivatives bearing 1,3,8-triazaspiro[4,5]decan-4-one or piperidine-3-carboxamide moiety as novel Type-I1/2 ALK inhibitors. Bioorg Chem. 2020;94:103456.
   PubMed Web of Science ®Google Scholar
• Tu CH, Lin WH, Peng YH, et al. Pyrazolylamine derivatives reveal the conformational switching between type I and type II binding modes of anaplastic lymphoma kinase (ALK). J Med Chem. 2016;59(8):3906–3919. DOI:10.1021/acs.jmedchem.6b00106
   PubMed Web of Science ®Google Scholar
• Shiba-Ishii A, Johnson TW, Dagogo-Jack I, et al. Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer. Nat Cancer. 2022;3(6):710–722. DOI:10.1038/s43018-022-00399-6
   PubMedGoogle Scholar
• Yoda S, Lin JJ, Lawrence MS, et al. Sequential ALK inhibitors can select for lorlatinib-resistant compound ALK mutations in ALK-Positive lung cancer. Cancer Discov. 2018;8(6):714–729. DOI:10.1158/2159-8290.CD-17-1256
   PubMed Web of Science ®Google Scholar
• Powell CE, Yang G, Tan L, et al. Chemically induced degradation of anaplastic lymphoma kinase (ALK). J Med Chem. 2018;61(9):4249–4255. DOI:10.1021/acs.jmedchem.7b01655
   PubMed Web of Science ®Google Scholar
• ONXEO. A dbait molecule in combination with kinase inhibitor for the treatment of cancer. WO2020188015A1 (2020).
   Google Scholar
• Aviceda Ophthalmics, Inc. Sialic-acid ligand decorated therapeutics. WO2022060984A1 (2022).
   Google Scholar
• Russo A, Franchina T, Ricciardi GRR, et al. Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance. Expert Rev Anticancer Ther. 2016;16(6):615–623. DOI:10.1080/14737140.2016.1182427
   PubMed Web of Science ®Google Scholar